NEULAND LABORATORIES
|
The Current P/E Ratio of NEULAND LABORATORIES is 91.51.
| Share Price | ₹12,806.8 | Feb 27,2026 |
| Market Cap | ₹16,392.7 Cr | |
| Earnings-TTM | ₹179.1 Cr | TTM-Consolidated Results |
| Price/Earnings | 91.51x | Calculated as Market Cap/Earnings |
|---|---|---|
| Explore Stock Analytics | ||
Definition & Calculation of PE (Price/Earnings) ratio of NEULAND LABORATORIES
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹16,392.7 Cr] as on Feb 27,2026
(/) Earnings [ ₹179.1 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ 91.51x ]
Thus, for NEULAND LABORATORIES , the investors are currently willing to pay 91.51 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of NEULAND LABORATORIES !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of NEULAND LABORATORIES over the last five years.
Historical PE (Price/Earnings) ratio chart of NEULAND LABORATORIES
PE Ratio Performance Analysis for NEULAND LABORATORIES
- NEULAND LABORATORIES 's p/e ratio for fiscal years ending Mar2025 to Mar2021 averaged 30.88x.
- NEULAND LABORATORIES 's operated at median p/e ratio of 26.86x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, NEULAND LABORATORIES 's p/e ratio peaked in Mar2025 at 59.57x.
- NEULAND LABORATORIES 's p/e ratio hit its five-year low in Mar2023 of 14.12x.
How does NEULAND LABORATORIES 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
| Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
|---|---|---|---|
| NEULAND LABORATORIES | 179.13 | 91.51 | 16,392.7 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 11,001.40 | 37.91 | 417,028.0 |
| DIVIS LABORATORIES LTD | 2,479.00 | 68.67 | 170,237.0 |
| CIPLA LTD | 4,544.70 | 23.95 | 108,861.0 |
| TORRENT PHARMACEUTICALS LTD | 2,272.00 | 64.61 | 146,801.0 |
| DR REDDYS LABORATORIES LTD | 5,508.70 | 19.50 | 107,435.0 |
| MANKIND PHARMA LTD | 1,796.65 | 51.64 | 92,784.1 |
| ZYDUS LIFESCIENCES LTD | 4,933.90 | 18.81 | 92,825.1 |
| LUPIN LTD | 4,669.18 | 22.53 | 105,182.0 |
| AUROBINDO PHARMA LTD | 3,513.20 | 20.19 | 70,947.8 |
| ABBOTT INDIA LTD | 1,524.13 | 36.94 | 56,300.3 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs NEULAND LABORATORIES 's P/E Ratio
| Top 10 Industry Peers | PE Ratio |
|---|---|
| Min industry PE | 18.81x |
| Max industry PE | 91.51x |
| Median industry PE | 36.94x |
| Average industry PE | 41.48x |
You may also like the below Video Courses